Matching articles for "antiepileptics"
Issue 1709 · August 19, 2024
Ganaxolone (Ztalmy) for CDKL5 Deficiency Disorder (online only)

The FDA has approved ganaxolone ( Ztalmy – Marinus) for oral treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients ≥2 years old. It is the first drug…

Med Lett Drugs Ther. 2024 Aug 19; 66(1709):e139-40 doi:10.58347/tml.2024.1709g
The FDA has approved ganaxolone ( Ztalmy – Marinus) for oral treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients ≥2 years old. It is the first drug to be approved in the US for this indication.
Issue 1708 · August 5, 2024
Drugs for Epilepsy

When used for the appropriate seizure type, antiseizure medications (ASMs) are roughly equivalent in efficacy. In addition to the seizure type, the choice of drug is usually based on factors such as ease of…

Med Lett Drugs Ther. 2024 Aug 5; 66(1708):121-8 doi:10.58347/tml.2024.1708a
When used for the appropriate seizure type, antiseizure medications (ASMs) are roughly equivalent in efficacy. In addition to the seizure type, the choice of drug is usually based on factors such as ease of use, spectrum of activity, adverse effects, interactions with other drugs, presence of comorbid conditions, suitability for elderly persons and those with childbearing potential, and cost. Treatment should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures persist, expert clinicians generally try at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs at the same time.
Issue 1679 · June 26, 2023
Brexpiprazole (Rexulti) for Agitation in Alzheimer's Dementia

The FDA has approved the oral second-generation antipsychotic drug brexpiprazole ( Rexulti – Otsuka/Lundbeck) for once-daily treatment of agitation associated with dementia due to Alzheimer's disease (AD).…

Med Lett Drugs Ther. 2023 Jun 26; 65(1679):99-101 doi:10.58347/tml.2023.1679b
The FDA has approved the oral second-generation antipsychotic drug brexpiprazole ( Rexulti – Otsuka/Lundbeck) for once-daily treatment of agitation associated with dementia due to Alzheimer's disease (AD). Brexpiprazole is the first drug to be approved in the US for this indication. It is also approved for treatment of schizophrenia and as an adjunct to antidepressants for treatment of major depressive disorder.
Issue 1678 · June 12, 2023
Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)

View the Comparison Table: Some Drugs for Migraine Prevention in Adults

Med Lett Drugs Ther. 2023 Jun 12; 65(1678):e100-2 doi:10.58347/tml.2023.1678c
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Issue 1678 · June 12, 2023 Free
Drugs for Migraine

An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe…

Med Lett Drugs Ther. 2023 Jun 12; 65(1678):89-96 doi:10.58347/tml.2023.1678a
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine in most patients without vascular disease. Treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Issue 1645 · March 7, 2022
Nonopioid Drugs for Pain

Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive…

Med Lett Drugs Ther. 2022 Mar 7; 64(1645):33-40
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Issue 1620 · March 24, 2021
Stiripentol (Diacomit) for Dravet Syndrome (online only)

The FDA has approved stiripentol (Diacomit – Biocodex) for treatment of seizures in patients ≥2 years old with Dravet syndrome who are also taking clobazam (Onfi) . Stiripentol, which has been available in…

Med Lett Drugs Ther. 2021 Mar 24; 63(1620):e1-3
The FDA has approved stiripentol (Diacomit – Biocodex) for treatment of seizures in patients ≥2 years old with Dravet syndrome who are also taking clobazam (Onfi) . Stiripentol, which has been available in Europe, Canada, and Japan for many years, is the second drug to be approved in the US for this indication; cannabidiol oral solution (Epidiolex) , a purified marijuana product, was the first.
Issue 1608 · October 5, 2020
Drugs for Migraine

An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe…

Med Lett Drugs Ther. 2020 Oct 5; 62(1608):153-60
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine headache pain in most patients without vascular disease. Early treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Issue 1605 · August 24, 2020
Cenobamate (Xcopri) for Focal Seizures

The FDA has approved cenobamate ( Xcopri – SK Life Science) for oral treatment of partial-onset (focal) seizures in adults.

Med Lett Drugs Ther. 2020 Aug 24; 62(1605):134-6
The FDA has approved cenobamate ( Xcopri – SK Life Science) for oral treatment of partial-onset (focal) seizures in adults.
Issue 1596 · April 20, 2020
Intranasal Diazepam (Valtoco) and Midazolam (Nayzilam) for Seizure Clusters

The FDA has approved nasal spray formulations of the benzodiazepines diazepam ( Valtoco — Neurelis) and midazolam ( Nayzilam — UCB) for acute treatment of intermittent episodes of frequent seizure activity…

Med Lett Drugs Ther. 2020 Apr 20; 62(1596):63-4
The FDA has approved nasal spray formulations of the benzodiazepines diazepam ( Valtoco — Neurelis) and midazolam ( Nayzilam — UCB) for acute treatment of intermittent episodes of frequent seizure activity (seizure clusters). Diazepam rectal gel ( Diastat, Diastat AcuDial , and generics) has been used for this indication for many years.
Issue 1585 · November 18, 2019
Cannabis and Cannabinoids

Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of…

Med Lett Drugs Ther. 2019 Nov 18; 61(1585):179-82
Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of cannabis. CBD, unlike THC, does not produce intoxication or euphoria.
Issue 1562 · December 17, 2018
Drugs for Chronic Insomnia

Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. Pharmacologic treatment should be used in addition to CBT-I when CBT-I alone is not effective.

Med Lett Drugs Ther. 2018 Dec 17; 60(1562):201-5
Cognitive behavioral therapy for insomnia (CBT-I) is recommended for initial treatment of chronic insomnia. Pharmacologic treatment should be used in addition to CBT-I when CBT-I alone is not effective.
Issue 1559 · November 5, 2018
Cannabidiol (Epidiolex) for Epilepsy

The FDA has approved cannabidiol oral solution ( Epidiolex – Greenwich Biosciences) for treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in patients ≥2 years old.…

Med Lett Drugs Ther. 2018 Nov 5; 60(1559):182-4
The FDA has approved cannabidiol oral solution ( Epidiolex – Greenwich Biosciences) for treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in patients ≥2 years old. Cannabidiol (CBD) is a cannabinoid constituent of the marijuana plant (Cannabis sativa) . It is the first natural marijuana product to be approved by the FDA for any indication and the first drug to be approved in the US for treatment of Dravet syndrome. Stiripentol (Diacomit) , which is not a marijuana product, was also recently approved by the FDA for treatment of Dravet syndrome in combination with clobazam ( Onfi) and will be reviewed in a future issue.
Issue 1549 · June 18, 2018
Erenumab (Aimovig) for Migraine Prevention

The FDA has approved erenumab-aooe ( Aimovig – Amgen/Novartis), a once-monthly, subcutaneously-injected, monoclonal antibody against the calcitonin gene-related peptide receptor, for preventive treatment of…

Med Lett Drugs Ther. 2018 Jun 18; 60(1549):101-3
The FDA has approved erenumab-aooe ( Aimovig – Amgen/Novartis), a once-monthly, subcutaneously-injected, monoclonal antibody against the calcitonin gene-related peptide receptor, for preventive treatment of migraine in adults. It is the first drug in its class to be approved by the FDA.
Issue 1549 · June 18, 2018 Free
In Brief: A Potentially Fatal Immune Reaction to Lamotrigine

The FDA has warned that the antiepileptic and mood-stabilizing drug lamotrigine ( Lamictal , and generics) can rarely cause hemophagocytic lymphohistiocytosis (HLH), a serious and potentially fatal…

Med Lett Drugs Ther. 2018 Jun 18; 60(1549):105
The FDA has warned that the antiepileptic and mood-stabilizing drug lamotrigine ( Lamictal , and generics) can rarely cause hemophagocytic lymphohistiocytosis (HLH), a serious and potentially fatal immune-related reaction. 1 HLH, which can be familial, occurs most often in infants, but can occur at any age. Often induced by Epstein-Barr Virus infection (HIV infection and non-Hodgkin's lymphoma are other common triggers), HLH is characterized by an unremitting activation of CD8+ T cells and macrophages. 2 If untreated, it causes organ damage, particularly in the liver, bone marrow, and CNS; organ failure and death occur within months after onset. 3 Clinical features can include fever and rash, splenomegaly, hepatitis, cytopenias, elevated triglyceride levels or low fibrinogen levels, hyperferritinemia, hemophagocytosis, decreased or absent natural killer cell activity, and elevated blood CD25 levels. 4 The optimal treatment for drug-induced HLH is unclear. Treatment of HLH generally involves use of corticosteroids and blood products, sometimes augmented by aggressive immunosuppression with the cytotoxic drug etoposide ( Toposar , and generics). The anti-CD52 antibody alemtuzumab (Lemtrada) can be added in refractory HLH cases, 5 and allogeneic hematopoietic cell transplantation has been used in genetic cases. Since lamotrigine first became available in 1994, five confirmed and three suspected cases of HLH associated with its use have been reported. All of these cases occurred within 24 days of starting treatment and required hospitalization. One death was reported; in the other cases, improvement occurred after discontinuation of lamotrigine and treatment of HLH. Because initial signs and symptoms of HLH are nonspecific, the condition can be confused with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), another potentially fatal, multiorgan, immune-related adverse reaction associated with lamotrigine use. 1,6 Patients being treated successfully with lamotrigine should continue taking it. Clinicians should monitor patients taking lamotrigine for signs and symptoms of HLH, especially during the first few weeks after starting the drug. FDA Drug Safety Communication: FDA warns of serious immune system reaction with seizure and mental health medicine lamotrigine (Lamictal). Available at: www.fda.gov. Accessed June 7, 2018. M Ramos-Casals et al. Adult haemophagocytic syndrome. Lancet 2014; 383:1503. SA Parikh et al. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc 2014; 89:484. JI Henter et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48:124. RA Marsh et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 2013; 60:101. SH Kardaun et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169:1071. Download complete U.S. English article
Issue 1540 · February 12, 2018
Nonopioid Drugs for Pain

Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. Use of opioids for pain will be reviewed in a future issue.

Med Lett Drugs Ther. 2018 Feb 12; 60(1540):24-32
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. Use of opioids for pain will be reviewed in a future issue.
Issue 1526 · July 31, 2017
Drugs for Epilepsy

Treatment of epilepsy should begin with a single antiepileptic drug (AED), increasing its dosage gradually until seizures are controlled or adverse effects become intolerable. If seizures persist, specialists…

Med Lett Drugs Ther. 2017 Jul 31; 59(1526):121-30
Treatment of epilepsy should begin with a single antiepileptic drug (AED), increasing its dosage gradually until seizures are controlled or adverse effects become intolerable. If seizures persist, specialists generally recommend trying at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs concurrently. When used for the appropriate seizure type, AEDs are roughly equivalent in efficacy. Drug choice is usually based on factors such as ease of use, adverse effects, drug interactions, presence of comorbidities, and cost.
Issue 1526 · July 31, 2017
Comparison Table: Some Oral Antiepileptic Drugs (online only)

View the Comparison Table: Some Oral Antiepileptic Drugs

Med Lett Drugs Ther. 2017 Jul 31; 59(1526):e130-6
View the Comparison Table: Some Oral Antiepileptic Drugs
Issue 1514 · February 13, 2017
Drugs for Migraine

An oral nonopioid analgesic may be sufficient for treatment of mild to moderate migraine without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine. Use of…

Med Lett Drugs Ther. 2017 Feb 13; 59(1514):27-32
An oral nonopioid analgesic may be sufficient for treatment of mild to moderate migraine without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine. Use of a triptan early in an attack when pain is still mild to moderate in intensity improves headache response and reduces recurrence rates.
Issue 1514 · February 13, 2017
Comparison Table: Some Drugs for Migraine Prevention in Adults (online only)

View the Comparison Table: Some Drugs for Migraine Prevention in Adults

Med Lett Drugs Ther. 2017 Feb 13; 59(1514):e31-2
View the Comparison Table: Some Drugs for Migraine Prevention in Adults
Issue 1501 · August 15, 2016
Drugs for Bipolar Disorder

Bipolar disorder is characterized by intermittent episodes of mania and/or depression. Even with maintenance treatment, recurrences of manic or (more frequently) depressive episodes are common. Some of the…

Med Lett Drugs Ther. 2016 Aug 15; 58(1501):103-6
Bipolar disorder is characterized by intermittent episodes of mania and/or depression. Even with maintenance treatment, recurrences of manic or (more frequently) depressive episodes are common. Some of the drugs and dosages recommended here have not been approved by the FDA for use in bipolar disorder.
Issue 1500 · August 1, 2016
Cannabis and Cannabinoids

In the US, 25 states and the District of Columbia now permit some medical use of botanical marijuana (Cannabis sativa) . It has been used for centuries to treat various ailments, but non-standardization of…

Med Lett Drugs Ther. 2016 Aug 1; 58(1500):97-8
In the US, 25 states and the District of Columbia now permit some medical use of botanical marijuana (Cannabis sativa) . It has been used for centuries to treat various ailments, but non-standardization of dosage makes available data difficult to interpret. Cannabis contains >60 pharmacologically active cannabinoids.
Issue 1499 · July 18, 2016
Brivaracetam (Briviact) for Epilepsy

Brivaracetam ( Briviact – UCB), an analog of levetiracetam ( Keppra , and others), has been approved by the FDA for adjunctive treatment of partial-onset seizures in patients ≥16 years old. New drugs for…

Med Lett Drugs Ther. 2016 Jul 18; 58(1499):95-6
Brivaracetam ( Briviact – UCB), an analog of levetiracetam ( Keppra , and others), has been approved by the FDA for adjunctive treatment of partial-onset seizures in patients ≥16 years old. New drugs for epilepsy are often approved initially only as adjunctive treatment for partial seizures.
Issue 1497 · June 20, 2016
Spritam - A New Formulation of Levetiracetam for Epilepsy

The FDA has approved a rapidly disintegrating tablet formulation of the antiepileptic drug levetiracetam ( Spritam – Aprecia) for adjunctive treatment of partialonset, myoclonic, and primary generalized…

Med Lett Drugs Ther. 2016 Jun 20; 58(1497):78-9
The FDA has approved a rapidly disintegrating tablet formulation of the antiepileptic drug levetiracetam ( Spritam – Aprecia) for adjunctive treatment of partialonset, myoclonic, and primary generalized tonicclonic seizures. Oral and intravenous formulations of levetiracetam ( Keppra , and generics) have been available for years. Although approved by the FDA only as adjunctive therapy, levetiracetam is commonly used as monotherapy for partial-onset and generalized seizures and may also be effective in treating absence seizures and seizures of Lennox-Gastaut syndrome.
Issue 1472 · July 6, 2015
Drugs for Insomnia

Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications, and "natural" remedies. Behavioral approaches such as cognitive behavioral therapy, which are not discussed…

Med Lett Drugs Ther. 2015 Jul 6; 57(1472):95-8
Pharmacological treatment of insomnia includes prescription drugs, non-prescription medications, and "natural" remedies. Behavioral approaches such as cognitive behavioral therapy, which are not discussed here, are also used. Pharmacologic treatment and behavioral therapy are often combined.
Issue 1462 · February 16, 2015
Diet, Drugs, and Surgery for Weight Loss

Adults with a body mass index (BMI) between 25 and 29.9 kg/m 2 are considered overweight. Those with a BMI ≥30 are considered obese. Losing even a small amount of weight and increasing physical activity can…

Med Lett Drugs Ther. 2015 Feb 16; 57(1462):21-8
Adults with a body mass index (BMI) between 25 and 29.9 kg/m 2 are considered overweight. Those with a BMI ≥30 are considered obese. Losing even a small amount of weight and increasing physical activity can prevent some of the complications of obesity, particularly type 2 diabetes. Diet and exercise are the preferred methods for losing weight, but long-term failure rates are high. Several drugs have been approved by the FDA for weight reduction, but adherence is poor, adverse effects are common, and patients usually regain the lost weight when the drug is stopped. Bariatric surgery can produce substantial weight loss and significantly reduce obesity-related comorbidities; long-term data on its safety are encouraging, but still limited. Guidelines for the management of overweight or obese adults have recently been published.
Issue 1457 · December 8, 2014 Free
In Brief: Topiramate Extended-Release Capsules (Qudexy XR) (online only)

The FDA has approved a new extended-release capsule formulation of topiramate ( Qudexy XR – Upsher Smith), which can be opened and sprinkled on food for patients who have difficulty swallowing tablets or…

Med Lett Drugs Ther. 2014 Dec 8; 56(1457):e126
The FDA has approved a new extended-release capsule formulation of topiramate ( Qudexy XR – Upsher Smith), which can be opened and sprinkled on food for patients who have difficulty swallowing tablets or capsules, for treatment of epilepsy. Qudexy XR was marketed as a branded drug in March 2014 and as a generic drug four months later. An earlier extended-release formulation (Trokendi XR) must be swallowed whole. Trokendi XR is approved for initial monotherapy in patients ≥10 years old with partial-onset seizures or primary generalized tonic-clonic seizures and for adjunctive therapy in patients ≥6 years old with partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome. Qudexy XR has been approved for the same indications, but the indication for adjunctive therapy has been extended to children ≥2 years old. Topiramate has been available for many years in immediate-release formulations ( Topamax , and others) for the same indications for patients ≥2 years old. Trokendi XR and Qudexy XR both appear to be bioequivalent to immediate-release formulations of topiramate; whether they are bioequivalent to one another has not been established. Download complete U.S. English article
Issue 1447 · July 21, 2014
A Responsive Neurostimulator Device (RNS System) for Epilepsy

The FDA has approved the use of a responsive neurostimulator device ( RNS System – NeuroPace) for adjunctive treatment of adults with partial-onset seizures that are not controlled with ≥2 antiepileptic…

Med Lett Drugs Ther. 2014 Jul 21; 56(1447):63
The FDA has approved the use of a responsive neurostimulator device ( RNS System – NeuroPace) for adjunctive treatment of adults with partial-onset seizures that are not controlled with ≥2 antiepileptic drugs and who have frequent and disabling seizures and no more than 2 epileptogenic foci.
Issue 1443 · May 26, 2014
Eslicarbazepine Acetate (Aptiom) for Epilepsy

Eslicarbazepine acetate ( Aptiom – Sunovion) has been approved by the FDA for adjunctive treatment of partial-onset seizures in adults. New drugs for epilepsy are often approved by the FDA initially only as…

Med Lett Drugs Ther. 2014 May 26; 56(1443):42-3
Eslicarbazepine acetate ( Aptiom – Sunovion) has been approved by the FDA for adjunctive treatment of partial-onset seizures in adults. New drugs for epilepsy are often approved by the FDA initially only as adjunctive treatment for partial seizures. Eslicarbazepine acetate is a prodrug of eslicarbazepine, which is the S-isomer of the active metabolite of oxcarbazepine. Oxcarbazepine itself is similar to carbamazepine. Both oxcarbazepine and carbamazepine are available generically.
Issue 1435 · February 3, 2014
Perampanel (Fycompa) for Epilepsy

Perampanel (per am’ pa nel; Fycompa – Eisai), a first-in-class noncompetitive AMPA receptor antagonist, has been approved by the FDA for adjunctive treatment of partial-onset seizures in patients ≥12…

Med Lett Drugs Ther. 2014 Feb 3; 56(1435):9-10
Perampanel (per am’ pa nel; Fycompa – Eisai), a first-in-class noncompetitive AMPA receptor antagonist, has been approved by the FDA for adjunctive treatment of partial-onset seizures in patients ≥12 years old. New drugs for epilepsy are often initially approved by the FDA as adjunctive treatment for partial seizures.
Issue 136 · December 1, 2013
Drugs for Migraine

Treatment of migraine in the emergency department, which may involve use of intravenous drugs, is not discussed here.

Treat Guidel Med Lett. 2013 Dec; 11(136):107-12
Treatment of migraine in the emergency department, which may involve use of intravenous drugs, is not discussed here.
Issue 1430 · November 25, 2013 Free
In Brief: Ezogabine (Potiga) Toxicity

The FDA recently announced changes in the labeling of ezogabine ( Potiga – GSK/Valeant) to warn about the risks of retinal abnormalities, possible vision loss, and bluish skin discoloration, all of which…

Med Lett Drugs Ther. 2013 Nov 25; 55(1430):96
The FDA recently announced changes in the labeling of ezogabine ( Potiga – GSK/Valeant) to warn about the risks of retinal abnormalities, possible vision loss, and bluish skin discoloration, all of which could be permanent. 1 Ezogabine was approved in 2011 for adjunctive treatment of partial-onset seizures in adults. 2 The FDA first warned about these risks in April 2013. 3 At that time, skin discoloration had developed in 38 of an estimated 605 patients (6.3%) who had taken the drug (most for ≥2 years) in various studies. Retinal pigment abnormalities were found in 11 of 36 patients who had eye examinations; some of these patients had impaired visual acuity, but baseline visual acuity assessments were not available. The new label recommends limiting the use of ezogabine to patients who have not responded adequately to several alternative antiepileptic drugs. Patients taking the drug should have a baseline eye exam and follow-up exams every 6 months. 1. FDA Drug Safety Communication: FDA approves label changes for anti-seizure drug Potiga (ezogabine) describing risk of retinal abnormalities, potential vision loss, and skin discoloration. Available at www.fda.gov. Accessed November 18, 2013. 2. Ezogabine (Potiga) for epilepsy. Med Lett Drugs Ther 2012; 54:65. 3. FDA Drug Safety Communication: Anti-seizure drug Potiga (ezogabine) linked to retinal abnormalities and blue skin discoloration. Available at www.fda.gov. Accessed November 18, 2013. Download complete U.S. English article
Issue 1428 · October 28, 2013
Topiramate Extended-Release (Trokendi XR) for Epilepsy

The FDA has approved a once-daily extended-release (ER) formulation of the antiepileptic topiramate ( Trokendi XR – Supernus) for initial monotherapy in patients ≥10 years old with partial onset seizures…

Med Lett Drugs Ther. 2013 Oct 28; 55(1428):87-8
The FDA has approved a once-daily extended-release (ER) formulation of the antiepileptic topiramate ( Trokendi XR – Supernus) for initial monotherapy in patients ≥10 years old with partial onset seizures or primary generalized tonic-clonic seizures and for adjunctive therapy in patients ≥6 years old with partial onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome. Topiramate has been available for many years as an immediate-release (IR) formulation ( Topamax , and generics) for the same indications in patients ≥2 years old
Issue 130 · June 1, 2013
Drugs for Psychiatric Disorders

Drugs are not the only treatment for psychiatric illness. Psychotherapy remains an important component in the management of these disorders, and cognitive behavioral therapy (CBT) can be used for many of them…

Treat Guidel Med Lett. 2013 Jun; 11(130):53-64
Drugs are not the only treatment for psychiatric illness. Psychotherapy remains an important component in the management of these disorders, and cognitive behavioral therapy (CBT) can be used for many of them as well. Electroconvulsive therapy (ECT) has a long history of efficacy and safety when drugs are ineffective or cannot be used.
Issue 128 · April 1, 2013
Drugs for Pain

Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less…

Treat Guidel Med Lett. 2013 Apr; 11(128):31-42
Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids and is often treated with adjuvant drugs such as antidepressants and antiepileptics. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Issue 1397 · August 20, 2012
Ezogabine (Potiga) for Epilepsy

The FDA has approved ezogabine (ee-ZOE-ga-been; Potiga – GSK/Valeant) for oral adjunctive treatment of partial-onset seizures in adults. Ezogabine is available in Europe as retigabine (Trobalt) .

Med Lett Drugs Ther. 2012 Aug 20; 54(1397):65-7
The FDA has approved ezogabine (ee-ZOE-ga-been; Potiga – GSK/Valeant) for oral adjunctive treatment of partial-onset seizures in adults. Ezogabine is available in Europe as retigabine (Trobalt) .
Issue 1385 · March 5, 2012
Clobazam (Onfi) for Lennox-Gastaut Syndrome

Clobazam ( Onfi – Lundbeck), an oral benzodiazepine, has been approved by the FDA for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥2 years old. It has been…

Med Lett Drugs Ther. 2012 Mar 5; 54(1385):18-9
Clobazam ( Onfi – Lundbeck), an oral benzodiazepine, has been approved by the FDA for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥2 years old. It has been available in Canada (Frisium) and other countries for years for treatment of anxiety and many types of epilepsy.
Issue 104 · April 1, 2011
Diet, Drugs and Surgery for Weight Loss

Adults with a body mass index (BMI=kg/m 2 ) of 25-<30 are considered overweight; those with a BMI of ≥30 are considered obese.

Treat Guidel Med Lett. 2011 Apr; 9(104):17-22
Adults with a body mass index (BMI=kg/m 2 ) of 25-<30 are considered overweight; those with a BMI of ≥30 are considered obese.
Issue 102 · February 1, 2011
Drugs for Migraine

Drugs for treatment of migraine are listed in Table 2 on page 9. Drugs for prevention of migraine are listed in Table 3 on page 10. Treatment of migraine in the emergency room, which may involve use of…

Treat Guidel Med Lett. 2011 Feb; 9(102):7-12
Drugs for treatment of migraine are listed in Table 2 on page 9. Drugs for prevention of migraine are listed in Table 3 on page 10. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Issue 93 · May 1, 2010
Drugs for Depression and Bipolar Disorder

Drugs are not the only treatment for mood disorders. Psychotherapy remains an important component in the management of these disorders, and electroconvulsive therapy (ECT) has a long history of efficacy and…

Treat Guidel Med Lett. 2010 May; 8(93):35-42
Drugs are not the only treatment for mood disorders. Psychotherapy remains an important component in the management of these disorders, and electroconvulsive therapy (ECT) has a long history of efficacy and safety when drugs are ineffective, poorly tolerated or cannot be used. Some drugs are recommended here for indications that have not been approved by the FDA.
Issue 1332 · February 22, 2010
Vigabatrin (Sabril) for Epilepsy

The FDA has approved vigabatrin (vye gá ba trin; Sabril – Lundbeck) for oral use as add-on therapy for complex partial seizures in adults who are refractory to several antiepileptic drugs and as monotherapy…

Med Lett Drugs Ther. 2010 Feb 22; 52(1332):14-6
The FDA has approved vigabatrin (vye gá ba trin; Sabril – Lundbeck) for oral use as add-on therapy for complex partial seizures in adults who are refractory to several antiepileptic drugs and as monotherapy for infantile spasms. Vigabatrin has been available in other countries for many years. Because of its potential for retinal toxicity, it will be available in the US only through a restricted distribution program called SHARE (Support, Help and Resources for Epilepsy). Prescribers and pharmacists distributing the drug must register, and patients must undergo visual field testing.
Issue 1323 · October 19, 2009
Generic Drugs Revisited

The equivalence of generic drugs to their brand-name precursors continues to be controversial. The last Medical Letter review of this subject (2002) concluded that well-documented therapeutic inequivalence…

Med Lett Drugs Ther. 2009 Oct 19; 51(1323):81-2
The equivalence of generic drugs to their brand-name precursors continues to be controversial. The last Medical Letter review of this subject (2002) concluded that well-documented therapeutic inequivalence between brand-name and FDA-approved generic drugs had not been reported. Is that still true? New data have become available for some drugs.
Issue 1315 · June 29, 2009
Lacosamide for Epilepsy

The FDA has approved lacosamide ( Vimpat - UCB Pharma) for oral or intravenous (IV) use as add-on therapy in adults with partial-onset seizures.

Med Lett Drugs Ther. 2009 Jun 29; 51(1315):50-2
The FDA has approved lacosamide ( Vimpat - UCB Pharma) for oral or intravenous (IV) use as add-on therapy in adults with partial-onset seizures.
Issue 1307 · March 9, 2009
Rufinamide (Banzel) for Epilepsy

Rufinamide (Banzel - Eisai), a triazole derivative structurally unrelated to other marketed antiepileptic drugs (AEDs), has been approved by the FDA for treatment of seizures associated with Lennox-Gastaut…

Med Lett Drugs Ther. 2009 Mar 9; 51(1307):18-20
Rufinamide (Banzel - Eisai), a triazole derivative structurally unrelated to other marketed antiepileptic drugs (AEDs), has been approved by the FDA for treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥4 years old.
Issue 1301 · December 15, 2008 Free
Drugs That May Cause Psychiatric Symptoms

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness,…

Med Lett Drugs Ther. 2008 Dec 15; 50(1301):100-3
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression. Click here to view the free full article.
Issue 70 · June 1, 2008
Drugs for Epilepsy

Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures continue and further dosage increases…

Treat Guidel Med Lett. 2008 Jun; 6(70):37-46
Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures continue and further dosage increases appear inadvisable because of adverse effects, most Medical Letter consultants generally prescribe at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs at the same time. Most antiepileptic drugs initially approved by the FDA only as adjunctive therapy for partial seizures may also be effective for other types of seizures and as monotherapy. Studies suggest that when used for the appropriate seizure type, antiepileptic drugs are roughly equivalent in efficacy. The choice of a drug is usually based on factors such as ease of use, adverse effects and cost.
Issue 67 · March 1, 2008
Drugs for Migraine

Some drugs for treatment of migraine attacks are listed in table 2 on page 18. Drugs for prevention of migraine are listed in table 3 on page 20. Treatment of migraine in the emergency room, which may involve…

Treat Guidel Med Lett. 2008 Mar; 6(67):17-22
Some drugs for treatment of migraine attacks are listed in table 2 on page 18. Drugs for prevention of migraine are listed in table 3 on page 20. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Issue 39 · November 1, 2005
Drugs for Epilepsy

Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures continue and further dosage increases…

Treat Guidel Med Lett. 2005 Nov; 3(39):75-82
Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures continue and further dosage increases appear inadvisable because of adverse effects, most Medical Letter consultants generally prescribe at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs at the same time. Most antiepileptic drugs initially approved by the FDA only as adjunctive therapy for partial seizures may also be effective for other types of seizures and as monotherapy.
Issue 1217 · September 12, 2005
Pregabalin (Lyrica) for Neuropathic Pain and Epilepsy

Pregabalin ( Lyrica - Pfizer), a structural analog of gamma-aminobutyric acid (GABA) similar to gabapentin ( Neurontin - Pfizer, and others), which recently became available generically, has been approved by…

Med Lett Drugs Ther. 2005 Sep 12; 47(1217):75-6
Pregabalin ( Lyrica - Pfizer), a structural analog of gamma-aminobutyric acid (GABA) similar to gabapentin ( Neurontin - Pfizer, and others), which recently became available generically, has been approved by the FDA for treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and diabetic peripheral neuropathy (DPN), and for adjunctive treatment of partial onset seizures in adults with epilepsy.
Issue 1201 · January 31, 2005
Topiramate (Topamax) for Prevention of Migraine

Patients with frequent, severe or disabling migraine headaches may benefit from taking a drug to prevent the attacks. Beta-blockers traditionally have been the prophylactic treatment of choice, but in recent…

Med Lett Drugs Ther. 2005 Jan 31; 47(1201):9-10
Patients with frequent, severe or disabling migraine headaches may benefit from taking a drug to prevent the attacks. Beta-blockers traditionally have been the prophylactic treatment of choice, but in recent years some antiepileptic drugs such as valproate ( Depakote , and others) and topiramate (Topamax) have also been used for this indication. Valproate was approved by the FDA for such use in 1996. Now topiramate has also been approved.
Issue 9 · May 1, 2003
Drugs for Epilepsy

Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures continue and further dosage increases…

Treat Guidel Med Lett. 2003 May; 1(9):57-64
Treatment of epilepsy should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures continue and further dosage increases appear inadvisable because of adverse effects, most Medical Letter consultants generally prescribe at least one and sometimes a second alternative drug as monotherapy before considering use of two drugs at the same time. Most antiepileptic drugs initially approved by the FDA only for adjunctive therapy are probably also effective as monotherapy. Many of the drugs used to treat epilepsy interact with each other (see table beginning on page 63) and with other drugs; for interactions with other drugs, see The Medical Letter Handbook of Adverse Drug Interactions, 2003. The treatment of status epilepticus is not included here.
Issue 1134 · July 8, 2002
Drugs That May Cause Psychiatric Symptoms

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously…

Med Lett Drugs Ther. 2002 Jul 8; 44(1134):59-62
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.
Issue 1093 · November 27, 2000
Drugs that may cause Cognitive Disorders in the Elderly

Older patients are especially susceptible to drug-induced cognitive impairment. They are more likely to be taking multiple drugs, to have higher blood levels of those drugs because of renal or hepatic…

Med Lett Drugs Ther. 2000 Nov 27; 42(1093):111-2
Older patients are especially susceptible to drug-induced cognitive impairment. They are more likely to be taking multiple drugs, to have higher blood levels of those drugs because of renal or hepatic dysfunction, and to have pre-existing cognitive problems that make it difficult to detect the role of drugs causing new symptoms or making old ones worse.